AMAG Pharmaceuticals on Monday earned expanded FDA approval for its chronic kidney disease treatment Feraheme.
Here are three things to know.
1. The FDA first approved Feraheme in 2009 to treat iron deficiency anemia in adults with chronic kidney disease.
2. The drug may now also be used to treat all adults with IDA who do not respond to or are intolerant to oral iron.
3. The expanded approval doubles the amount of patients who may benefit from the drug, which is administered as an injection.